| Literature DB >> 24779869 |
Julian G Simmons, Sarah L Whittle, George C Patton, Paul Dudgeon, Craig Olsson, Michelle L Byrne, Lisa K Mundy, Marc L Seal, Nicholas B Allen1.
Abstract
BACKGROUND: Puberty is a critical developmental phase in physical, reproductive and socio-emotional maturation that is associated with the period of peak onset for psychopathology. Puberty also drives significant changes in brain development and function. Research to date has focused on gonadarche, driven by the hypothalamic-pituitary-gonadal axis, and yet increasing evidence suggests that the earlier pubertal stage of adrenarche, driven by the hypothalamic-pituitary-adrenal axis, may play a critical role in both brain development and increased risk for disorder. We have established a unique cohort of children who differ in their exposure to adrenarcheal hormones. This presents a unique opportunity to examine the influence of adrenarcheal timing on brain structural and functional development, and subsequent health outcomes. The primary objective of the study is to explore the hypothesis that patterns of structural and functional brain development will mediate the relationship between adrenarcheal timing and indices of affect, self-regulation, and mental health symptoms collected across time (and therefore years of development). METHODS/Entities:
Mesh:
Substances:
Year: 2014 PMID: 24779869 PMCID: PMC4012090 DOI: 10.1186/1471-2431-14-115
Source DB: PubMed Journal: BMC Pediatr ISSN: 1471-2431 Impact factor: 2.125
Eligibility criteria for iCATS
| Parental and child consent in CATS; | History of head trauma or loss of consciousness; |
| Completed Wave 1 of CATS in full, i.e., parent/guardian q’s, and child q’s, anthropometric measurements, and saliva sample; | History of clinically significant developmental or intellectual disorder; |
| Child aged between 8.5 and 9.5 years at the time of their CATSparticipation; | Clinically significant DHEA, DHEA-S, Testosterone; |
| Written consent provided by parent for their own participation; | Indications of claustrophobia; |
| Written consent provided by the parent and the child for the child’s participation; and, | Long-term use of steroidal or amphetamine based medications; |
| Verbal consent provided by the child. | Short-term current use (i.e., < 2 weeks) of amphetamines; |
| Short-term current use of steroidal medications will be reviewed on a case-by-case basis; | |
| Presence or likelihood of internal or external non-removable ferrous metals; | |
| Inability or unwillingness of participant or parent/guardian to provide informed consent. |